Moomoo AIのまとめ
CR Group L.P., a significant stakeholder in T2 Biosystems, Inc. [TTOO], reported a series of acquisitions of common stock on April 12, 2024. The transactions were made through various entities associated with CR Group L.P. and were all indirect acquisitions. A total of 682,036 shares were acquired by CRG Partners III L.P., 424,716 shares by CRG Partners III - Parallel Fund (A) L.P., 136,409 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,647,315 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 390,142 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions significantly increased CR Group L.P.'s holdings in T2 Biosystems, with the total number of shares held after the transactions amounting to 4,104,838. The nature of the shares is indirect, and the transactions are classified as grants, awards, or other acquisitions.
CR Group L.P., a significant stakeholder in T2 Biosystems, Inc. [TTOO], reported a series of acquisitions of common stock on April 12, 2024. The transactions were made through various entities associated with CR Group L.P. and were all indirect acquisitions. A total of 682,036 shares were acquired by CRG Partners III L.P., 424,716 shares by CRG Partners III - Parallel Fund (A) L.P., 136,409 shares by CRG Partners III (Cayman) Unlev AIV I L.P., 1,647,315 shares by CRG Partners III (Cayman) Lev AIV I L.P., and 390,142 shares by CRG Partners III - Parallel Fund B (Cayman) L.P. These acquisitions significantly increased CR Group L.P.'s holdings in T2 Biosystems, with the total number of shares held after the transactions amounting to 4,104,838. The nature of the shares is indirect, and the transactions are classified as grants, awards, or other acquisitions.
T2バイオシステムズの重要な株主であるCR Group L.P.は、2024年4月12日に普通株式の一連の取得を報告しました。これらの取引は、CR Group L.P.に関連するさまざまな実体を通じて行われた間接的な取得でした。CRG Partners III L.P.が682,036株、CRG Partners III - Parallel Fund (A) L.P.が424,716株、CRG Partners III (Cayman) Unlev AIV I L.P.が136,409株、CRG Partners III (Cayman) Lev AIV I L.P.が1,647,315株、...すべて展開
T2バイオシステムズの重要な株主であるCR Group L.P.は、2024年4月12日に普通株式の一連の取得を報告しました。これらの取引は、CR Group L.P.に関連するさまざまな実体を通じて行われた間接的な取得でした。CRG Partners III L.P.が682,036株、CRG Partners III - Parallel Fund (A) L.P.が424,716株、CRG Partners III (Cayman) Unlev AIV I L.P.が136,409株、CRG Partners III (Cayman) Lev AIV I L.P.が1,647,315株、CRG Partners III - Parallel Fund B (Cayman) L.P.が390,142株を取得しました。これらの取得により、CR Group L.P.のT2 Biosystemsへの持ち株数は大幅に増加し、取引後の総持ち株数は4,104,838株に達しました。この株の性質は間接的であり、取引はグラント、アワード、またはその他の取得として分類されます。
役に立った
役に立たない